PharmaTher’s Ketamine Formulation Receives CRL From FDA
The FDA Demanded Minor Clarifications From The Canadian Firm
After sharing multiple updates to the regulatory status of its ketamine formulation, PharmaTher received a complete response letter from the FDA, which required minor information and clarifications from the company.
